Article

BNT162b2 vaccine booster dose protection: A nationwide study from Israel

2021-08-31

Abstract excerpt

<h4>Background</h4> On July 30, 2021, a third (booster) dose of the Pfizer BNT162b2 vaccine was approved in Israel for individuals 60 years or older who had been fully vaccinated (i.e., received two doses) at least five months previously. Here, we estimate the reduction in relative risk for confirmed infection and severe COVID-19 provided by the booster dose. <h4>Methods</h4> 1,144,690 individuals aged 60y and old...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 470b947b-5f15-5bed-9158-e3b7c6ca63fe
DOI: 10.1101/2021.08.27.21262679

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

BNT162b2 vaccine booster dose protection: A nationwide study from IsraelDOI 10.1101/2021.08.27.21262679Read

Relative Effectiveness of Four Doses Compared to Three Dose of the BNT162b2 Vaccine in IsraelSemantic proximity Read

Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort studySemantic proximity Read

Protection against omicron severe disease 0-7 months after BNT162b2 boosterSemantic proximity Read

The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidenceSemantic proximity Read

The Effectiveness of the First Dose of BNT162b2 Vaccine in Reducing SARS-CoV-2 Infection: Real-World EvidenceSemantic proximity Read

Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 VaccineSemantic proximity Read

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in QatarSemantic proximity Read

BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure; Analysis of Household Members of COVID-19 PatientsSemantic proximity Read

Fractional versus standard BNT162b2 boosters after non-mRNA priming in Mongolia: 24-month immunogenicity and safety evidence from a randomised controlled trialSemantic proximity Read

Second Booster Vaccine Dose for Older Adults and COVID-19 Mortality During the Omicron SurgeSemantic proximity Read

Effectiveness of BNT162b2 booster doses in England: an observational study in OpenSAFELY-TPPSemantic proximity Read

Twelve-month follow-up of immunogenicity and safety of fractional and standard booster doses of the Pfizer-BioNTech COVID-19 vaccine in adults primed with ChAdOx1, BBIBP-CorV, or GAM-CoV-Vac: a randomised controlled trialSemantic proximity Read